Privia Health Group, Inc. (NASDAQ:PRVA – Get Free Report) CFO David Mountcastle sold 600 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $27.57, for a total transaction of $16,542.00. Following the completion of the sale, the chief financial officer directly owned 186,128 shares in the company, valued at approximately $5,131,548.96. This trade represents a 0.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
David Mountcastle also recently made the following trade(s):
- On Thursday, July 2nd, David Mountcastle sold 24,734 shares of Privia Health Group stock. The shares were sold at an average price of $27.50, for a total value of $680,185.00.
- On Friday, June 26th, David Mountcastle sold 17,196 shares of Privia Health Group stock. The shares were sold at an average price of $25.18, for a total value of $432,995.28.
- On Monday, May 11th, David Mountcastle sold 3,385 shares of Privia Health Group stock. The stock was sold at an average price of $22.60, for a total transaction of $76,501.00.
- On Monday, May 4th, David Mountcastle sold 1,206 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total transaction of $30,150.00.
- On Friday, May 1st, David Mountcastle sold 7,179 shares of Privia Health Group stock. The stock was sold at an average price of $25.03, for a total transaction of $179,690.37.
Privia Health Group Trading Down 1.0%
Shares of NASDAQ:PRVA opened at $27.49 on Friday. The company has a 50-day moving average price of $23.76 and a 200-day moving average price of $23.14. The company has a market cap of $3.46 billion, a price-to-earnings ratio of 171.82, a price-to-earnings-growth ratio of 2.20 and a beta of 0.83. Privia Health Group, Inc. has a 12 month low of $18.77 and a 12 month high of $27.86.
Hedge Funds Weigh In On Privia Health Group
Analyst Upgrades and Downgrades
Several equities analysts have commented on PRVA shares. Zacks Research downgraded Privia Health Group from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Canaccord Genuity Group reduced their price target on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Evercore set a $26.00 price objective on shares of Privia Health Group in a research report on Wednesday, April 8th. Weiss Ratings upgraded shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 2nd. Finally, Barclays reduced their target price on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 26th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.15.
Check Out Our Latest Research Report on PRVA
Privia Health Group News Roundup
Here are the key news stories impacting Privia Health Group this week:
- Positive Sentiment: RBC Capital reiterated its Buy rating on Privia Health Group, which supports the bullish case for the stock. RBC Capital Keeps Their Buy Rating on Privia Health Group (PRVA)
- Neutral Sentiment: Short-interest data showed no meaningful short position changes, so this does not appear to be a major driver of the stock today.
- Neutral Sentiment: CFO David Mountcastle sold a small number of shares under a pre-arranged 10b5-1 trading plan, which is generally viewed as routine insider activity rather than a strong negative signal. Privia Health Group (NASDAQ:PRVA) CFO David Mountcastle Sells 600 Shares
- Negative Sentiment: Zacks Research downgraded Privia Health Group from Hold to Strong Sell, which could pressure sentiment despite the stock’s recent strength. Privia Health Group was downgraded by Zacks Research from “hold” to “strong sell”.
Privia Health Group Company Profile
Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.
Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.
Read More
- Five stocks we like better than Privia Health Group
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
- MarketBeat Week in Review – 07/06 – 07/10
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
